- A new once-a-day weight loss pill, orforglipron, has been hailed as an “important advancement” in type 2 diabetes care following a new study.
- The study compared orforglipron against oral semaglutide, an existing tablet version of a GLP-1 receptor agonist, finding it superior for blood sugar reduction and weight loss.
- Patients taking orforglipron lost between six and eight per cent of their body weight, compared to four to five per cent for those on semaglutide.
- A key advantage of orforglipron is that it can be taken without restrictions on food or water intake, unlike oral semaglutide, which requires an empty stomach.
- While more patients on orforglipron reported gastrointestinal side effects, experts from Diabetes UK welcomed the findings, highlighting the importance of diverse treatment options.
IN FULL
